- $1.35bn
- $1.00bn
- 44
- 25
- 48
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.87 | ||
| Price to Tang. Book | 3.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.72% | ||
| Return on Equity | -28.23% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 8.38 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Directors
- Georges Gemayel CHM (61)
- Jason Meyenburg PRE (44)
- Brian Piekos CFO (47)
- Marc Uknis OTH (56)
- Jim Tananbaum DRC (58)
- Carl Gordon IND (56)
- David Lubner IND (57)
- Tuyen Ong IND (46)
- Jason Rhodes IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 25th, 2020
- Public Since
- August 12th, 2020
- No. of Shareholders
- 19
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 29,639,885
- Address
- 321 Arsenal Street, Suite 101, WATERTOWN, 02472
- Web
- https://www.discmedicine.com/
- Phone
- +1 6176749274
- Auditors
- Ernst & Young LLP
Upcoming Events for IRON
Q3 2024 Disc Medicine Inc Earnings Release
Similar to IRON
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Disc Medicine share price?
As of Today at 20:17 UTC, shares in Disc Medicine are trading at $44.18. This share price information is delayed by 15 minutes.
How has the Disc Medicine share price performed this year?
Shares in Disc Medicine last closed at $44.18 and the price had moved by -18.55% over the past 365 days. In terms of relative price strength the Disc Medicine share price has underperformed the S&P500 Index by -35.19% over the past year.
What are the analyst and broker recommendations for Disc Medicine?
The overall consensus recommendation for Disc Medicine is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Disc Medicine dividend yield?
Disc Medicine does not currently pay a dividend.
Does Disc Medicine pay a dividend?
Disc Medicine does not currently pay a dividend.
When does Disc Medicine next pay dividends?
Disc Medicine does not currently pay a dividend.
How do I buy Disc Medicine shares?
To buy shares in Disc Medicine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Disc Medicine?
As of the previous close price of $44.18, shares in Disc Medicine had a market capitalisation of $1.31bn.
Where are Disc Medicine shares listed?
Here are the trading details for Disc Medicine:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IRON
What kind of share is Disc Medicine?
Based on an overall assessment of its quality, value and momentum Disc Medicine is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Disc Medicine share price forecast for 2024?
The analyst consensus target price for shares in Disc Medicine is $64.33. That is 45.61% above the last closing price of $44.18.
Analysts covering Disc Medicine currently have a consensus Earnings Per Share (EPS) forecast of -$4.87 for the next financial year.
What is the trend in the Disc Medicine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Disc Medicine. Over the past six months, its share price has underperformed the S&P500 Index by -33.56%.
As of the last closing price of $44.18, shares in Disc Medicine were trading -11.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Disc Medicine PE Ratio?
The Disc Medicine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $44.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Disc Medicine?
Disc Medicine's management team is headed by:
- Georges Gemayel - CHM
- Jason Meyenburg - PRE
- Brian Piekos - CFO
- Marc Uknis - OTH
- Jim Tananbaum - DRC
- Carl Gordon - IND
- David Lubner - IND
- Tuyen Ong - IND
- Jason Rhodes - IND